WEDI presents 2013 roadmap, discloses steering committee members

Laura Pedulli | | Health Exec | Policy & Regulations

The Workgroup for Electronic Data Interchange (WEDI) announced the completion of its 2013 WEDI report roadmap and disclosed the final list of executive steering committee members and advisors, according to a press announcement.

WEDI will form workgroups to focus on the following four topic priorities: (1) patient engagement through improved data access; (2) alternative payment models and requisite business, information and exchange requirements; (3) better aligning administrative and clinical information capture, linkage and exchange through existing standards; and (4) business cases for innovative encounter models through current and future technologies.

More information on the workgroups is here, and a full list of WEDI report executive committee members is available here.

 

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.